Open main menu

Psychiatrienet β

Olanzapine-Haloperidol LA

Revision as of 10:51, 14 August 2009 by Verena (talk | contribs) (Created page with '{{Drugswitch | from = Olanzapine | to = Haloperidol_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | view = | info = {{Alternatief}} }}')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Olanzapine
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AH03
Medscape Olanzapine
EMEA zyprexa
PubChem 4585
PubMed Olanzapine
Drugs.com olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine
Haloperidol
long acting
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol

Switch medication from Olanzapine to Haloperidol_LA.[7] [8]

Nietinrijdenbord.png Stop Olanzapine
  • Week 1-3: approx. 75% of initial dose
  • Week 4-6: approx. 50% of initial dose
  • Week 7-9: approx. 25% of initial dose
  • Week 10: stop
Eenrichtingbord.png Start Haloperidol_LA
  • Day 1: Start depot according general dosing advice (Dotted line in graph)
Infobord.png More information
  • Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
  1. ↑ 1.0 1.1 1.2 1.3 KNMP; Informatorium Medicamentorum 2023; Monografie "olanzapine" (Dutch)
  2. ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
  3. ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
  4. ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  5. ↑ 5.0 5.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  6. ↑ 6.0 6.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  7. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  8. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Olanzapine-Haloperidol_LA&oldid=2944"